Tang Jiayi, Ni Huadong, Yao Ming
Department of Anesthesiology and Pain Research Center, The First Hospital of Jiaxing or The Affiliated Hospital of Jiaxing University, Jiaxing, People's Republic of China.
Drug Des Devel Ther. 2025 Jun 19;19:5283-5292. doi: 10.2147/DDDT.S511613. eCollection 2025.
This study aimed to determine the median effective dose (ED50) and effective dose 95% (ED95) of nalbuphine for alleviating moderate-severe catheter-related bladder discomfort (CRBD) after ureteroscopic lithotripsy (URL) in male patients using probit regression analysis.
This retrospective study analyzed anesthesia records of all male patients who underwent URL and received nalbuphine under general anesthesia at Jiaxing University Affiliated Hospital between August 2023 and August 2024. Patients were categorized into four groups based on nalbuphine dosage: 0.025, 0.05, 0.075, and 0.10 mg/kg. Data on patient demographics, CRBD scores, agitation scores, the Ramsay sedation scale, and urinary catheter-related pain (UCRP) scores were collected 5 min after laryngeal mask removal. Hemodynamic parameters, including mean blood pressure, heart rate (HR), and oxygen saturation (SPO), were collected at various time points: post-operation (T0), and at immediately (T1), 5 (T2), 10 (T3), 20 (T4), and 30 min (T5) after laryngeal mask removal. The incidence of adverse events was documented. Probit regression analysis was employed to calculate the ED50 and ED95 of nalbuphine for alleviating moderate-severe CRBD.
Data from 76 anesthesia records were retrieved. CRBD, agitation, and UCRP scores decreased with increasing nalbuphine doses, while the Ramsay sedation scores increased. No significant differences were observed in hemodynamic parameters across dose groups at any time point (P > 0.05). Similarly, the incidence of adverse effects did not differ significantly among the groups (P > 0.05). Probit regression analysis revealed that the ED50 of nalbuphine for alleviating moderate-severe CRBD following URL in male patients was 0.03 mg/kg (95% confidence interval [CI]: 0.013-0.046), while the ED95 was 0.108 mg/kg (95% CI: 0.085-0.188).
Nalbuphine is a safe and effective agent for mitigating CRBD, with an ED50 of 0.03 mg/kg and ED95 of 0.108 mg/kg.
本研究旨在通过概率回归分析确定纳布啡缓解男性患者输尿管镜碎石术（URL）后中重度导管相关膀胱不适（CRBD）的半数有效剂量（ED50）和95%有效剂量（ED95）。
本回顾性研究分析了2023年8月至2024年8月在嘉兴学院附属医院接受URL并在全身麻醉下使用纳布啡的所有男性患者的麻醉记录。根据纳布啡剂量将患者分为四组：0.025、0.05、0.075和0.10mg/kg。在拔除喉罩后5分钟收集患者人口统计学数据、CRBD评分、躁动评分、 Ramsay镇静评分和导尿管相关疼痛（UCRP）评分。在不同时间点收集血流动力学参数，包括平均血压、心率（HR）和血氧饱和度（SPO）：术后（T0），以及拔除喉罩后即刻（T1）、5分钟（T2）、10分钟（T3）、20分钟（T4）和30分钟（T5）。记录不良事件的发生率。采用概率回归分析计算纳布啡缓解中重度CRBD的ED50和ED95。
检索到76份麻醉记录的数据。随着纳布啡剂量增加，CRBD、躁动和UCRP评分降低，而Ramsay镇静评分升高。在任何时间点，各剂量组的血流动力学参数均无显著差异（P>0.05）。同样，各组间不良反应发生率无显著差异（P>0.05）。概率回归分析显示，纳布啡缓解男性患者URL后中重度CRBD的ED50为0.03mg/kg（95%置信区间[CI]：0.013-0.046），而ED95为0.108mg/kg（95%CI：0.085-0.188）。
纳布啡是缓解CRBD的一种安全有效的药物，ED50为0.03mg/kg，ED95为0.108mg/kg。
Zotero 插件